Equities

China Health Industries Holdings Inc

CHHE:QBB

China Health Industries Holdings Inc

Actions
  • Price (USD)0.325
  • Today's Change0.00 / 0.00%
  • Shares traded345.00
  • 1 Year change-61.76%
  • Beta--
Data delayed at least 15 minutes, as of Aug 28 2024 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.

  • Revenue in USD (TTM)95.95k
  • Net income in USD-1.36m
  • Incorporated2004
  • Employees32.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aytu Biopharma Inc93.76m-13.68m14.75m150.00--0.4469--0.1573-2.65-2.6518.215.530.67922.422.93625,053.30-9.91-33.56-25.58-52.8165.3256.89-14.60-73.810.69230.2160.352--11.1096.5684.33------
Pharmacyte Biotech Inc0.00-17.24m14.82m2.00--0.5611-----1.93-1.930.004.920.00----0.000.5012-7.420.5333-7.68------------0.00-------299.38------
Talphera Inc398.00k-13.70m15.29m15.00--1.20--38.43-0.6353-0.63230.01850.74910.0187----26,533.33-64.37-22.60-78.11-28.55-----3,443.22-714.87----0.00-----21.26-119.16---34.33--
Cara Therapeutics Inc11.00m-111.08m15.69m55.00--1.35--1.43-2.04-2.040.20170.21150.10631.102.10199,927.30-107.38-35.76-132.61-40.8274.66---1,010.20-162.104.48--0.00---49.929.26-38.65--100.66--
DH Enchantment Inc100.00-173.19k16.09m1.00------160,915.00-0.0002-0.00020.00-0.00120.04380.1493--100.00-7,579.43------0.00---173,190.00--0.0029-14.85-----95.43--59.53------
Nexgel Inc5.01m-3.39m17.19m19.00--3.85--3.43-0.5722-0.57220.84640.65890.49423.036.44263,631.60-35.74-44.61-48.15-56.1923.745.02-72.33-180.980.8135--0.1992--99.6613.0633.48------
Cumberland Pharmaceuticals, Inc.37.79m-10.38m17.62m91.00--0.6681--0.4663-0.7328-0.73282.671.870.45010.86433.17415,225.80-12.35-7.03-17.75-9.5282.5879.95-27.45-17.641.26-38.850.382---5.856.15-12.73---36.17--
Cyclo Therapeutics Inc1.13m-20.74m18.68m8.00------16.50-0.9104-0.91040.0474-0.17850.2420.400213.16141,553.80-443.08-132.22---215.1791.5690.37-1,831.29-1,114.040.4283-------21.761.25-29.81---3.95--
TherapeuticsMD Inc996.00k-4.83m19.14m1.00--0.6918--19.22-0.4348-0.55380.08892.400.0212--0.5048996,000.00-10.31-53.35-13.13-111.6145.0886.67-485.34-236.57----0.00---98.14-39.53-816.85------
China Health Industries Holdings, Inc.95.95k-1.36m21.30m32.00------221.99-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
Polypid Ltd0.00-24.70m24.26m59.00--10.34-----9.65-9.650.000.33370.00----0.00-107.89-76.92-164.39-89.61-----------24.210.8425------39.67---42.34--
Bio Essence Corp593.21k-1.02m25.09m12.00------42.29-0.0278-0.01560.0158-0.04580.3305--21.20---57.09-46.10----25.0533.89-172.74-111.21---59.997.03---11.27-10.94-52.03---48.19--
BioXcel Therapeutics Inc2.40m-107.83m25.96m74.00------10.80-3.56-3.560.074-1.840.02340.59413.8732,472.97-104.93-74.57-150.29-84.0643.07---4,487.39-32,300.742.25-10.103.59--268.00---8.02---43.26--
KALA BIO Inc0.00-38.72m26.72m43.00--1.94-----13.95-13.950.002.980.00----0.00-60.45-57.83-78.16-69.32--57.06---1,553.61---11.360.7174---100.00--5.85---17.31--
Acasti Pharma Inc0.00-11.45m27.58m32.00--0.4646-----1.22-1.220.005.850.00-------16.04-31.68-16.57-33.95-------56,271.43---37.800.00------69.71---47.16--
Dare Bioscience Inc2.84m-7.20m27.60m23.00--10.33--9.72-1.07-1.070.35790.31260.1213--3.85123,462.20-30.76-109.51-191.39-246.260.8477---253.60-1,104.55----0.00---71.92--2.54--121.37--
Data as of Aug 28 2024. Currency figures normalised to China Health Industries Holdings Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.